While India was busy diagnosing itself with “cricket fever” post T20 season, Metropolis quietly diagnosed something rarer—23% revenue growth. Apparently, you don’t need stethoscopes when you have acquisitions, AI chatbots, and TruHealth packages. Quarter 1, usually a sickly child for diagnostics, suddenly came out doing push-ups. But hold that celebratory thali—the PAT chart isn’t smiling as much. Read on, because the real test results are buried deeper in the transcript.
2. At a Glance
Revenue up 23% – Acquisitions acted like Red Bull shots.
Organic revenue up 13.2% – Turns out patients really do like checkups.
EBITDA margin 24.7% – Path labs flex harder than most gyms.
PAT (Organic) up 21% – CFO claims it’s not spreadsheet steroids.
Group PAT flat-ish at ₹45 Cr – Thanks to Core Diagnostics dragging like a bad cold.
Stock up ~8% – Traders only heard “23% growth” and skipped the pathology section.
3. Management’s Key Commentary
Quote: “AI in diagnostics is happening globally, but India is far from en masse use.” (Translation: Relax, no robot will take your blood sample just yet.)
Quote: “POC diagnostics are useful in rural/semi-urban markets, but not cheaper or more accurate than labs.” (Translation: Nice gadget, but still not replacing our central lab cash cows.)
Quote: “GLP-1 therapies are a $500M India market by 2030, driving more testing.” (Translation: Weight-loss injections = lifelong lab subscription plans.)
Quote: “We posted 13.2% organic revenue growth, despite Q1 being soft.” (Translation: Imagine what we’ll do in flu season. 💉)
Quote: “Our oncology centre of excellence will position us as leaders in onco-diagnostics.” (Translation: Cancer tests = serious business, serious margins.)
Quote: “Ambika Diagnostics acquisition at 5x EBITDA is highly accretive.” (Translation: We basically stole Kolhapur’s favorite lab and called it synergy.)
Quote: “Core Diagnostics EBITDA turned positive after integration.” (Translation: Earlier it was bleeding red ink; now it’s just pale pink.)
4. Numbers Decoded
Source table
Metric
Value (Q1 FY26)
YoY Change
One-Line Analysis
Revenue – The Hero
₹381 Cr (Group)
+23%
Acquisitions + organic boost did the heavy lifting.
